The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …

Fifteen years ago, a panel of experts representing the full spectrum of cardiovascular
disease (CVD) research and practice assembled at a workshop to examine the state of …

ContextIt is commonly suggested that more than 50% of patients with coronary heart disease
(CHD) lack any of the conventional risk factors (cigarette smoking, diabetes, hyperlipidemia …

The content of these European Society of Cardiology (ESC) Guidelines has been published
for personal and educational use only. No commercial use is authorized. No part of the ESC …

In patients with stable CAD, PCI can be considered a valuable initial mode of
revascularization in all patients with objective large ischaemia in the presence of almost …

Summary Background Platelet glycoprotein IIb/IIIa inhibitors have been shown to reduce
cardiac complications in patients undergoing percutaneous coronary intervention. The …

The clinical presentations of ischaemic heart disease include stable angina pectoris, silent
ischaemia, unstable angina, myocardial infarction, heart failure, and sudden death. For …

This article discusses platelet active drugs as part of the Seventh American College of Chest
Physicians Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based …

Background Coronary-stent implantation is frequently performed for treatment of acute
myocardial infarction. However, few studies have compared stent implantation with primary …

Background Aggregation of platelets is the pathophysiologic basis of the acute coronary
syndromes. Eptifibatide, a synthetic cyclic heptapeptide, is a selective high-affinity inhibitor …